Table 1.
Results of evaluation
| # |
Association of interest MI ((95%CI) |
Mediators for association of interest MI (95%CI) |
Result *(D/I/E) |
RS ** | |
| RX-SX | RX-DX | DX-SX | |||
| 1 | Metolazone-Shortness of Breath 0.086(0.075–0.097) |
Metolazone-Hypertensive Disease 0.526(0.495–0.557) | Hypertensive Disease-Shortness of Breath 0.132(0.113–0.152) | I | I |
| 2 | Metolazone-Headache 0.070(0.059–0.083) |
Metolazone-Hypertensive Disease 0.526(0.495–0.557) |
Hypertensive Disease-Headache 0.084(0.072–0.095) |
E | E |
| 3 | Metolazone-constipation 0.034 (0.023–0.046) |
Metolazone-Hypertensive Disease 0.526(0.495–0.557) |
Hypertensive Disease-constipation 0.019(0.009–0.028) | E | D |
| 4 | Rosiglitazone-Headache 0.079 (0.068–0.091) |
Rosiglitazone-Diabetes 0.443(0.327–0.513) |
Diabetes-Headache 0.117(0.093–0.128) |
I | D |
| 5 | Rosiglitazone-Chest Pain 0.077(0.069–0.088) |
Rosiglitazone-Diabetes 0.443(0.327–0.513) |
Diabetes-Chest Pain 0.090(0.074–0.115) |
E | E |
| DX1 - SX | DX1 - DX2 | DX2 - SX | |||
| 6 | Hypertensive Disease-Shortness of Breath 0.132(0.113–0.152) | Hypertensive Disease-Heart Failure 0.651(0.563–0.738) | Heart Failure-Shortness of Breath 0.173(0.158–0.186) |
I | I |
| 7 | Diabetes-Chest Pain 0.131(0.115–0.148) |
Diabetes-Heart Failure 0.435(0.317–0.543) |
Heart Failure-Chest Pain 0.184(0.169–0.193) |
I | I |
DX: Disease; RX: Drug; SX: Symptom; *I: Indirect association; D; Direct association; E: Either association; ** RS: Reference Standard.